Mektovi OverviewBinimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers. It can be taken orally in tablet form. Mechanism of action Binimetinib is an inhibitor of mitogen-activated protein kinase kinase (MEK), or more specifically, a MAP2K inhibitor. MEK is part of the RAS pathway, which is involved in cell proliferation and survival. MEK is upregulated in many forms of cancer. Development In...
Read more Mektovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Binimetinib
Recent Mektovi Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 15mg